ArticleGastroenterology and hepatology from bed to bench2025
Can disulfiram modulate liver injury in CCl4-induced fibrosis in rats?
Article in Gastroenterology and hepatology from bed to bench, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: This study aimed to evaluate the hepatoprotective and antifibrotic effects of DSF in a rat model of CCl Background: Liver fibrosis is a chronic and potentially life-threatening condition characterized by fibroblast proliferation and excessive extracellular matrix deposition. Oxidative stress and inflammation are central mechanisms in its pathogenesis. Disulfiram (DSF), known for its antioxidant and potential antifibrotic properties, may attenuate liver injury. Methods: Thirty-five male Wistar rats were randomly divided into seven groups (n = 5 per group): Control, Oil, DSF 25 mg/kg, DSF 50 mg/kg, CCl Results: CCl Conclusion: Low-dose DSF demonstrated hepatoprotective effects through improvements in biochemical markers and hepatocyte morphology, but failed to significantly attenuate fibrosis. These findings suggest that lower DSF concentrations (< 25 mg/kg) may offer greater antifibrotic potential and should be further investigated in dose-response studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.